Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
HK$ 194.4
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
BeiGene Ltd. is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EB
Data is available to registered users only
Target Price
The average target price of 6160.HK is 242 and suggests 13% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendatio
Data is available to registered users only
Buy
Sell